Tislelizumab + Salvage Chemotherapy
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma
Trial Timeline
Dec 14, 2020 → Oct 13, 2025
NCT ID
NCT04486391About Tislelizumab + Salvage Chemotherapy
Tislelizumab + Salvage Chemotherapy is a phase 3 stage product being developed by BeOne Medicines for Classical Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04486391. Target conditions include Classical Hodgkin Lymphoma.
What happened to similar drugs?
0 of 1 similar drugs in Classical Hodgkin Lymphoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04486391 | Phase 3 | Terminated |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 29 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 42 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 35 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 31 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 31 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 39 |
| Panobinostat | Novartis | Phase 2 | 35 |
| PD1 | Innovent Biologics | Phase 2 | 35 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 33 |
| GEN3017 | Genmab | Phase 1/2 | 21 |